Emetrol helps to eliminate unpleasant symptoms that accompany chronic gastritis with impaired motility. The active substance of the drug – domperidone – is an antagonist of peripheral dopamine receptors localized in the wall of the stomach and duodenum. Besides, the drug increases tone and pressure of lower esophageal sphincter, accelerates gastric emptying, increases duodenal peristalsis and increases duration of antral and duodenal contractions. In addition, gastrokinetic action of emetrol increases antiemetic effect, which is due to blockade of dopamine receptors located in the chemoreceptor trigger zone on the floor of the fourth ventricle.
Features of use
Emetrol (Domperidone) should be used with caution in patients with mild hepatic and/or renal dysfunction. Due to the increased risk of ventricular arrhythmia, Domperidone is not recommended for use in patients with prolonged intervals of cardiac conduction, particularly QTc, patients with significant electrolyte imbalance (hypokalemia, hyperkalemia, hypomagnesemia) or bradycardia, or patients with background heart diseases, such as congestive heart failure. Electrolyte imbalances (hypokalemia, hyperkalemia, hypomagnesemia) and bradycardia are known to be conditions that increase proarrhythmogenic risk. In case of signs or symptoms that may be associated with cardiac arrhythmia, the use of Domperidone should be stopped, and the patient should immediately consult the doctor. Impaired renal function. The half-life of Domperidone in severe renal impairment is prolonged.
With long-term use, the dosing frequency of domperidone should be reduced to 1-2 times per day, depending on the severity of the impairment. It may also be necessary to reduce the dose. Antacids or antisecretory drugs should not be taken simultaneously with the drug emetrol, because they reduce oral bioavailability of emetrol. When concomitant use, the drug emetrol (domperidone) should be taken before meals, and antacids or antisecretory drugs – after meals. Application of domperidone with ketoconazole. Interaction studies with the oral form of ketoconazole have reported a prolongation of the QT interval. Although the significance of this study is not clearly established, alternative treatment should be chosen if antifungal therapy with ketoconazole is indicated. The following information regarding the risk of cardiovascular complications due to drugs containing Domperidone should be considered. Some epidemiological studies have shown that Emetrol (domperidone) may be associated with an increased risk of severe ventricular arrhythmias or sudden cardiac death. The risk of severe ventricular arrhythmias or sudden cardiac death may be higher in patients aged over 60 years or when using oral doses of emetrol more than 30 mg per day. Therefore, Domperidone should be used with caution in elderly patients. Patients over 60 years of age should consult their physician before taking the drug. Domperidone should be administered in adults and children in the most effective dose. The risk/benefit ratio of Domperidone use remains favorable. If you have established intolerance to some sugars, consult your doctor before taking this medicinal product.